News Column

Reports Summarize Gene Therapy Study Results from Beckman Research Institute (Efficient selection of genetically modified human T cells using...

June 30, 2014



Reports Summarize Gene Therapy Study Results from Beckman Research Institute (Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase)

By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on Biotechnology is now available. According to news reporting originating in Duarte, California, by NewsRx journalists, research stated, "Genetic modification of human T cells to express transgene-encoded polypeptides, such as tumor targeting chimeric antigen receptors, is an emerging therapeutic modality showing promise in clinical trials. The development of simple and efficient techniques for purifying transgene(+) T cells is needed to facilitate the derivation of cell products with uniform potency and purity."

The news reporters obtained a quote from the research from Beckman Research Institute, "Unlike selection platforms that utilize physical methods (immunomagnetic or sorting) that are technically cumbersome and limited by the expense and availability of clinical-grade components, we focused on designing a selection system on the basis of the pharmaceutical drug methotrexate (MTX), a potent allosteric inhibitor of human dihydrofolate reductase (DHFR). Here, we describe the development of self inactivating (SIN) lentiviral vectors that direct the coordinated expression of a CD19-specific chimeric antigen receptor (CAR), the human EGFRt tracking/suicide construct, and a methotrexate-resistant human DHFR mutein (huDHFR(FS); L22F, F31S). Our results demonstrate that huDHFR(FS) expression renders lentivirally transduced primary human CD45RO(+)CD62L(+) central memory T cells resistant to lymphotoxic concentrations of MTX up to 0.1??M. Our modular complementary DNA (cDNA) design insures that selected MTX-resistant T cells co-express functionally relevant levels of the CD19-specific CAR and EGFRt."

According to the news reporters, the research concluded: "This selection system on the basis of huDHFR(FS) and MTX has considerable potential utility in the manufacturing of clinical-grade T cell products."

For more information on this research see: Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase. Gene Therapy, 2013;20(8):853-60. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)

Our news correspondents report that additional information may be obtained by contacting M. Jonnalagadda, Departments of Cancer Immunotherapeutics and Tumor Immunology and Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, United States. Additional authors for this research include C.E. Brown, W.C. Chang, J.R. Ostberg, S.J. Forman and M.C Jensen (see also Biotechnology).

Keywords for this news article include: Biotechnology, Duarte, Reductase, California, United States, Enzymes and Coenzymes, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters